Twelves, C.J., O'Reilly, S.M., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (2 more authors) (1989) Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. British Journal of Cancer, 60 (6). pp. 938-941. ISSN 0007-0920
Abstract
Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated. Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial deterioration in liver biochemistry may occur before there is a response to epirubicin.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 1989 The Macmillan Press Ltd. |
Keywords: | Adult; Aged; Aspartate Aminotransferases; Bilirubin; Breast Neoplasms; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Time Factors |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 15 Feb 2021 13:44 |
Last Modified: | 15 Feb 2021 13:44 |
Status: | Published |
Publisher: | Springer Nature (for Cancer Research UK) |
Refereed: | Yes |
Identification Number: | 10.1038/bjc.1989.394 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:170595 |